# Peptides in 2 — Episode 15: Mazdutide

Evidence across borders. Final film in this group. Evidence cutoff: October 14, 2026. Published October 14, 2026.

Runtime 1:45; 1920×1080, 24 fps, stereo AAC. One continuous neutral narrator recording, normal generation speed and unchanged spoken pace. No inserted reading holds or secondary closing voice. Three original conceptual technology artworks, exact research graphics and a new low instrumental score. Scenes follow the actual recording, and the final takeaway moves forward once into the WPF sign-off.

## Measured sequence

| Seconds | Visual |
|---|---|
| 0.00–1.00 | Established WPF opening |
| 1.00–13.12 | Original freeze-dryer artwork; mazdutide and the finale theme |
| 13.12–25.58 | Lilly–Innovent roles and the 2019 China licence |
| 25.58–38.54 | GLORY-1 population, investigators and study groups |
| 38.54–51.82 | Week-48 signed estimates and true confidence intervals |
| 51.82–67.53 | Analysis choices, individual response and adverse events |
| 67.53–85.62 | China’s separate 2025 approval milestones |
| 85.62–97.48 | A coherent group takeaway: four evidence questions |
| 97.48–105.00 | One transition into the complete WPF closing |

## Scientific controls

Keep the GLORY-1 population and 48-week treatment-policy results together. Mark the primary endpoints as week 32. Retain the placebo gain, true confidence intervals and zero reference. Identify company licence history, investigators, sponsor role and China-specific approvals separately. Announcement months do not redefine legal approval-document dates. Do not add a next-film teaser or cross-trial ranking.

## Verification and deliverables

Check the complete export and all eight narration sections, clinical values, frame layout, reading contrast, soundtrack level, actual low-energy gaps and closing timing. Provide film, source pack, complete notes, exact script, captions, thumbnail and site-ready metadata. All generated scenes are illustrative and must not be presented as actual trial footage.